Core Insights - The medical services sector experienced a slight increase of 0.18% on August 22, with a net outflow of 494 million yuan in principal funds [1] - Among the constituent stocks, 21 rose while 22 fell, indicating mixed performance within the sector [1] Fund Flow Analysis - The top net outflow stocks included WuXi AppTec with 193 million yuan, Sanbo Brain Science with 162 million yuan, and Kailaiying with approximately 71.53 million yuan [1] - Other notable outflows were observed in Zhaoyan New Drug (52.94 million yuan) and Innovation Medical (44.23 million yuan) [1] Stock Performance - Haocen Medical saw a significant increase of 9.92% with a net inflow of 116 million yuan, representing 19.82% of its market [1] - Baihua Medicine and Dian Diagnostics also reported gains of 1.51% and 2.41%, with net inflows of 414.83 thousand yuan and 393.43 thousand yuan respectively [1] - Conversely, Chengda Pharmaceutical and Guangzheng Eye Care experienced declines of 3.38% and 2.09% respectively, with net outflows of 2149.15 thousand yuan and 1199.08 thousand yuan [1]

截至2025年8月21日收盘，三博脑科股价报61.25元，较前一交易日下跌2.47元，跌幅3.88%。当日成交 额10.09亿元，换手率10.19%。 风险提示：市场有风险，投资需谨慎。 来源：金融界 三博脑科是一家专注于神经外科领域的医疗服务企业，业务涵盖脑科疾病的诊断、治疗及康复。公司所 属板块包括医疗服务、精准医疗等。 消息面上，公司股东TBP3Doctors（HK）Limited计划减持不超过608.97万股，占公司总股本的3%。目 前TBP持有公司15.37%的股份。 资金流向方面，8月21日主力资金净流出1.58亿元，近五日累计净流出8.42亿元。 ...

Core Viewpoint - A total of 22 A-share listed companies disclosed share reduction plans, with no companies announcing share increases on the same day [1] Group 1: Companies and Their Reduction Plans - Dongfang Ocean plans to reduce its holdings by no more than 3% [2] - Nanmin Group's two shareholders intend to reduce their holdings by no more than 3.63% [2] - Xinhai Optoelectronics' shareholders Gao Zhan and Zhou Xuan plan to reduce their shares [2] - Yiming Food's shareholders will collectively reduce their holdings by no more than 3% [2] - Yingshi Sheng's shareholders plan to reduce their holdings by no more than 2% [2] - Jereh's vice chairman Wang Jili plans to reduce no more than 723,000 shares [2] - Hengyu Xintong's shareholders intend to reduce their holdings by no more than 2% [2] - Ruoyuchen's shareholder Langjing's shareholding will drop below 2% [2] - Zhongchumei's shareholder Wang Jing plans to reduce no more than 1% [2] - Jiangbolong's five employee shareholding platforms plan to reduce no more than 1.31% [2] - Puyuan Information's actual controller and its concerted actors plan to reduce their holdings by no more than 2.9951% [2] - Botuo Biological's actual controller Yu Xiuping plans to reduce no more than 3% [2] - Sanbo Brain Science's shareholder TBP plans to reduce no more than 3% [2] - Yijiahe's Huatai Zhanxin Investment and Daofeng Investment plan to reduce no more than 2% [2] - Rongzhirixin's controlling shareholder and concerted parties plan to reduce no more than 3% [2] - Taijin Investment's shareholders plan to reduce no more than 3% [2] - Xidian New Energy's shareholder Changjiang Chen Dao plans to reduce no more than 2% [2] - Huoshan's two shareholders plan to reduce a total of 5.45% [2] - Dongfang Zhaoye's chairman Feng Liming plans to reduce no more than 131,500 shares [2] - Nanjing New Hundred plans to reduce no more than 6 million shares of repurchased stock [2] - Xagong's shareholder Xiamen Kouhang plans to reduce no more than 1% [2] - Jinhongshun's shareholder Gaode Investment plans to reduce no more than 3% [2]

Shareholder Reduction - Shareholders Gao Zhan and Zhou Xuan of Xinhau Optoelectronics plan to reduce their holdings by a total of no more than 1.0176 million shares [1] - Shareholders Xinyue Investment, Mingniu Investment, and Chengyue Investment of Yiming Food plan to reduce their holdings by a total of no more than 12.03 million shares [1] - The consistent action party of shareholders holding more than 5% of Yingshisheng plans to reduce their holdings by no more than 2% [1] - Chairman and General Manager Nie Weihua of Rongzhi Rixin plans to reduce his holdings by no more than 1.40% [1] - Major shareholder Wang Jing of Zhongchumei plans to reduce his holdings by no more than 1.76 million shares [1] - Shareholder Huatai Zhanzheng Investment of Yijiahe plans to reduce their holdings by no more than 4.0972 million shares [1] - Actual controller Yu Xiuping of Botuo Biological plans to reduce his holdings by no more than 3% [1] Other Financial Information - Electric Science Cybersecurity reported a net loss of 170 million yuan in the first half of the year [1] - Ziaotai reported a net loss of 125 million yuan in the first half of the year [1]

Performance Disclosure - Muyuan Foods reported a revenue of 76.463 billion yuan for the first half of 2025, representing a year-on-year increase of 34.46%, with a net profit attributable to shareholders of 10.53 billion yuan, up 1169.77% year-on-year [1] - Shanghai Petrochemical reported a revenue of 39.52 billion yuan for the first half of 2025, a year-on-year decrease of 9.2%, with a net loss attributable to shareholders of 462 million yuan, transitioning from profit to loss [2] - Fuhuan Microelectronics reported a revenue of 688 million yuan for the first half of 2025, a year-on-year decrease of 14.04%, with a net profit attributable to shareholders of approximately 23.02 million yuan, down 78.1% year-on-year [3] Shareholding Changes - Botao Bio announced that its actual controller, Yu Xiuping, plans to reduce holdings by no more than 3% of the company's total shares, equating to approximately 4.48 million shares [4] - Sanbo Brain Science announced that shareholder TBP 3Doctors (HK) Limited plans to reduce holdings by no more than approximately 609,000 shares, accounting for 3% of the total share capital after excluding shares in the repurchase account [5] - Xiangshan Co. announced that two shareholders, Zhao Yukun and Chen Bo, reduced their holdings by a total of 5.45% of the company's shares, equating to 7.1996 million shares, with the reduction plan completed [6] Risk Matters - ST Zhongdi announced that 23.77% of the shares held by its controlling shareholder, totaling 71.1448 million shares, will be publicly auctioned from September 24 to 25, 2025, due to debt disputes, which may lead to a change in company control if the auction is successful [7] - Kailong Co. announced that its subsidiaries were fined a total of 1.762 million yuan for reaching a fixed price monopoly agreement, which is expected to reduce the company's net profit by approximately 1.3962 million yuan [8] - Tiansheng New Materials reported that Baoding Weishai New Materials Technology Co., Ltd. filed an appeal involving an amount of 802 million yuan, seeking to overturn a previous court ruling [9]

Performance Disclosure - Muyuan Foods reported a revenue of 76.463 billion yuan for the first half of 2025, representing a year-on-year increase of 34.46%, with a net profit attributable to shareholders of 10.53 billion yuan, up 1169.77% year-on-year [1] - Shanghai Petrochemical reported a revenue of 39.52 billion yuan for the first half of 2025, a year-on-year decrease of 9.2%, with a net loss attributable to shareholders of 462 million yuan, transitioning from profit to loss [2] - Fuhuan Microelectronics reported a revenue of 688 million yuan for the first half of 2025, a year-on-year decrease of 14.04%, with a net profit attributable to shareholders of approximately 23.02 million yuan, down 78.1% year-on-year [3] Shareholding Changes - Botao Biological announced that its actual controller, Yu Xiuping, plans to reduce holdings by no more than 3% of the company's total shares, equating to approximately 4.48 million shares [4] - Sanbo Brain Science announced that shareholder TBP 3Doctors (HK) Limited plans to reduce holdings by no more than approximately 609,000 shares, representing 3% of the total share capital after excluding shares in the repurchase account [5] - Xiangshan Co. announced that two shareholders, Zhao Yukun and Chen Bo, reduced their holdings by a total of 5.45% of the company's shares, equating to 7.1996 million shares, with the reduction plan completed [6] Risk Matters - ST Zhongdi announced that 23.77% of the shares held by its controlling shareholder, totaling 71.1448 million shares, will be publicly auctioned from September 24 to 25, 2025, due to debt disputes, which may lead to a change in company control [7] - Kailong Co. announced that its subsidiaries were fined a total of 1.762 million yuan for reaching a fixed price monopoly agreement, which is expected to reduce the company's net profit by approximately 1.3962 million yuan [8] - Tiansheng New Materials reported that Baoding Weishai New Materials Technology Co., Ltd. filed an appeal involving an amount of 802 million yuan, seeking to overturn a previous court ruling [9]

Group 1 - The stock price of Sanbo Brain Science closed at 63.72 yuan on August 20, 2025, down by 2.44 yuan, a decrease of 3.69% from the previous trading day [1] - The trading volume on that day was 227,709 hands, with a transaction amount of 1.451 billion yuan [1] - Sanbo Brain Science is a medical service provider focused on neurosurgery, with main businesses including medical services and supply chain operations [1] Group 2 - The company announced that a shareholder holding more than 5% of shares, TBP3Doctors (HK) Limited, plans to reduce its holdings by up to 6.09 million shares, accounting for 3% of the total share capital, within the next three months [1] - The reduction will occur through a centralized bidding method for up to 2.03 million shares and through block trading for up to 4.06 million shares [1] - On August 20, the net outflow of main funds for Sanbo Brain Science was 269.69 million yuan, representing 2.63% of the circulating market value [1]

Core Viewpoint - TBP 3Doctors (HK) Limited plans to reduce its stake in Sanbo Brain Science (301293) by up to 6.0897 million shares, representing 3% of the total share capital after excluding shares in the company's repurchase account [1] Summary by Relevant Sections - Shareholding Information - TBP currently holds 31.2054 million shares in Sanbo Brain Science, which accounts for 15.37% of the total share capital after excluding shares in the company's repurchase account [1]

格隆汇8月20日丨三博脑科(301293.SZ)公布，持有公司股份31,205,425股(占剔除公司回购专用账户股份 数量后总股本的15.37%)的持股5%以上股东TBP 3Doctors(HK)Limited(简称"TBP")计划在公告披露之日 起十五个交易日后的三个月内以集中竞价和大宗交易方式减持公司股份不超过6,089,694股(占剔除公司 回购专用账户股份数量后总股本的3.00%)。其中，通过集中竟价方式减持不超过2,029,898股(占剔除公 司回购专用账户股份数量后总股本的1.00%)，通过大宗交易方式减持不超过4,059,796股(占剔除公司回 购专用账户股份数量后总股本的2.00%)。 ...

来源：新浪证券-红岸工作室 三博脑科医院管理集团股份有限公司（以下简称"三博脑科"）近日发布关于持股5%以上股东减持股份 的预披露公告，股东TBP 3Doctors (HK) Limited计划减持公司股份。 减持股东及股份情况 TBP 3Doctors (HK) Limited目前持股数量为31,205,425股，占剔除公司回购专用账户股份数量后总股本 的15.37%，其所持股份全部为无限售条件流通股。股份来源为公司首次公开发行股票并上市前持有的 股份以及该等股份上市后资本公积金转增股本取得的股份。 减持计划详情 减持数量及占比：计划减持6,089,694股，占剔除公司回购专用账户股份数量后总股本的3.00%。其中， 通过集中竞价方式减持不超过2,029,898股（占剔除公司回购专用账户股份数量后总股本的1.00%），通 过大宗交易方式减持不超过4,059,796股（占剔除公司回购专用账户股份数量后总股本的2.00%）。若计 划减持期间内有派息、送股等除权除息事项，减持股份数将相应进行调整。 减持期间：自本公告披露之日起15个交易日后的3个月内。 减持价格：根据减持时的市场价格确定，并根据集中竞价、大宗交易 ...